Ernexa Therapeutics Inc. Share Repurchase Authorization
Ernexa Therapeutics Inc. (ERNA) had Share Repurchase Authorization of $12.00 million as of 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramAuthorizedAmount1 · last filed 2023-03-20
- 2022-12-31: Stock Repurchase Program, Authorized Amount $12.00M.
- 2022-09-30: Stock Repurchase Program, Authorized Amount $12.00M.
- 2022-06-30: Stock Repurchase Program, Authorized Amount $12.00M.
- 2022-03-31: Stock Repurchase Program, Authorized Amount $12.00M.
| Period end | Stock Repurchase Program, Authorized Amount |
|---|---|
| 2022-12-31 | $12.00M 10-K · filed 2023-03-20 |
| 2022-09-30 | $12.00M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $12.00M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $12.00M 10-Q · filed 2022-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |